Stock Events

Stock Events

BioRestorative Therapies 

0
38
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14MayExpected
Q1 2026
-3.43
-3.1
-2.76
-2.43
Expected EPS
-3.4292
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.25B
Mesoblast Limited specializes in regenerative medicine, competing directly in the development of cell-based therapies.
Vericel
VCEL
Mkt Cap2.06B
Vericel Corporation offers cell therapies for the treatment of patients with serious diseases and conditions, including cartilage repair, a key area for BioRestorative.
Biolife Solutions
BLFS
Mkt Cap1.72B
BioLife Solutions provides bioproduction tools and services, including cell and gene therapy solutions, directly supporting the same market as BioRestorative.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics develops autologous stem cell therapies for debilitating neurodegenerative diseases, overlapping with BioRestorative's therapeutic areas.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is focused on the development of gene-based therapies, which could compete with BioRestorative's cell therapy approaches in certain applications.
Editas Medicine
EDIT
Mkt Cap496.06M
Editas Medicine operates in the genome editing field, potentially competing with BioRestorative's approach to treating diseases through regenerative medicine.
Intellia Therapeutics
NTLA
Mkt Cap1.79B
Intellia Therapeutics is another key player in the CRISPR/Cas9 genome editing space, representing potential competition in the development of genetic and cell therapies.
Fate Therapeutics
FATE
Mkt Cap297.15M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, competing in the broader cell therapy market.

About

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Show more...
CEO
Katharyn Field
Employees
14
Country
United States
ISIN
US0906557055
WKN
000A42DVS

Listings

F
DE
9OF0.F
STU
DE
9OF.STU
MU
DE
9OF.MU
BOATS
BOATS
BRTX.BOATS

0 Comments

Share your thoughts

FAQ

What is BioRestorative Therapies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange BioRestorative Therapies stocks are traded under the ticker 9OF0.F.
How many employees does BioRestorative Therapies have?▼
As of September 09, 2026, the company has 14 employees.
In which sector is BioRestorative Therapies located?▼
BioRestorative Therapies operates in the Health & Wellness sector.
When did BioRestorative Therapies complete a stock split?▼
BioRestorative Therapies has not had any recent stock splits.
Where is BioRestorative Therapies headquartered?▼
BioRestorative Therapies is headquartered in MELVILLE, United States.